Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 99

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 99
---
 invalid or unenforceable, our ability to commercialize or license our technology could be adversely affected. Others have filed, and in the future are likely to file, patent applications covering products and technologies that are similar, identical or competitive to ours or important to our business. We cannot be certain that any patent application owned by a third party will not have priority over patent applications filed or in-licensed by us, or that we will not be involved in interference, opposition or invalidity proceedings before U.S. or non-U.S. patent offices. The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:

| ● | others may be able to make product                                                                                                    
 candidates or develop a platform similar to, or better than, ours in a way that is not covered by the claims of our licensed or owned 
 patents;                                                                                                                              |

| ● | others may be able to make compounds                                                                                            
 that are similar to our product candidates but that are not covered by the claims of patents we own or that are licensed to us; |

| ● | we or our prospective licensors                                                                                                        
 or future collaborators might not have been the first to make the inventions covered by any pending patent applications issued patents 
 that we own or license;                                                                                                                |

51

| ● | we or our prospective licensors                                                                                                                
 or future collaborators might not have been (or may not be in the future) the first to file patent applications for certain of our inventions; |

| ● | others may independently develop                                                                                              
 similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; |

| ● | our pending patent applications 
 may not lead to issued patents; |

| ● | issued patents that we own or                                                                              
 license may be held invalid or unenforceable as a result of legal challenges by our competitors or others; |

| ● | our competitors might conduct                                                                                                       
 R&D activities in countries where we do not have patent rights and then use the information learned from such activities to develop 
 competitive products for sale in our major commercial markets;                                                                      |

| ● | any patents that we obtain,                                                                                                          
 or are licensed to us, may not provide us with any competitive advantages or protection against competitors, or may be challenged by 
 third parties;                                                                                                                       |

| ● | we cannot predict the scope                                                                                                                   
 of protection of any patent issuing based on our patent applications, including whether the patent applications that